查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1540909

2024-2032 年蛋白質治療市場報告（按產品（單株抗體、人類胰島素、促紅血球生成素、凝血因子、融合蛋白等）、治療領域、功能和地區）

Protein Therapeutics Market Report by Product (Monoclonal Antibodies, Human Insulin, Erythropoietin, Clotting Factors, Fusion Protein, and Others), Therapy Area, Function, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 136 Pages | 商品交期: 2-3個工作天內

價格

2023年全球蛋白質治療市場規模達3,456億IMARC Group。癌症、糖尿病、心血管疾病和自體免疫疾病等慢性疾病的盛行率不斷上升，蛋白質工程技術的快速進步，生物製藥行業的不斷擴大以及產品在不同治療領域的廣泛應用是推動市場發展的一些因素。

蛋白質療法是一類利用蛋白質或胜肽來預防、控制或治癒疾病的醫學治療方法。這些療法旨在針對體內的特定分子或途徑，提供高度針對性的治療方法。他們為多種疾病提供創新的解決方案，包括癌症、自體免疫疾病、遺傳性疾病等。它們可以來自天然來源，也可以透過重組 DNA 技術生產，從而可以開發高度特異性和有效的療法。這些治療性蛋白質可以採取多種形式，包括單株抗體、生長因子、酵素和細胞激素。它們與體內的特定受體或分子相互作用，調節細胞過程，抑製或刺激免疫反應，或直接針對致病因子。蛋白質療法的優點在於其高特異性、效力和低毒性。與傳統的小分子藥物相比，它們通常具有更高的療效和更少的副作用。他們大大推進了醫學領域的發展，提供了新穎的治療選擇並改善了各種疾病的患者治療結果。

全球市場的主要驅動力是對個人化醫療的日益關注。與此一致的是，不斷增加的研發活動和不斷擴大的醫療基礎設施正在為市場做出巨大貢獻。此外，製造流程的進步預計將推動市場的發展。除此之外，基因工程、蛋白質合成和生產技術的突破提高了蛋白質治療的效率和有效性，對市場產生了積極影響。此外，癌症、糖尿病、心血管疾病和自體免疫疾病等慢性疾病的日益普及正在催化市場。此外，蛋白質療法在腫瘤學中的廣泛應用正在刺激市場。此外，藥物輸送系統的快速創新改善了蛋白質治療藥物的輸送，提高了其療效和患者依從性。緩釋製劑、奈米顆粒和標靶藥物遞送系統等新型遞送方法可透過增加蛋白質藥物的治療潛力來推動市場成長。

蛋白質治療市場趨勢/促進因素：

不斷增加的生物製藥研發投資

由於蛋白質藥物具有高特異性、有效性和標靶性，生物製藥公司和研究機構越來越關注其開發。生物製藥領域研發投資的增加正在推動蛋白質療法的進步。這些投資支持與蛋白質工程、藥物發現和配方最佳化相關的研究活動，從而開發新型和改進的蛋白質療法。此外，分配給研發的大量資金使研究人員能夠探索新的治療靶點，最佳化蛋白質結構以增強活性，並進行廣泛的臨床前和臨床試驗。這些努力透過引入針對各種疾病的創新療法，有助於擴大市場。此外，不斷成長的研發投資有助於擴大蛋白質療法的生產流程，使其更容易獲得且更具成本效益。這使得蛋白質藥物的商業化和市場滲透率得到提高。

生物相似藥的擴展

生物相似藥市場的擴張對市場做出了重大貢獻。生物相似藥是與已核准的參考蛋白治療藥物高度相似的生物藥物。隨著幾種重磅生物製劑的專利到期，生物相似藥市場正在迅速擴大。生物相似藥的出現為昂貴的蛋白質療法提供了具有成本效益的替代品，使患者和醫療保健系統更容易獲得它們。負擔能力的提高使患者能夠獲得必要的治療，從而推動市場成長。此外，生物相似藥的引入促進了市場競爭。競爭導致價格下降，鼓勵市場擴張，並為生物相似藥製造商和參考蛋白治療公司創造創新和改進產品的機會。此外，生物相似藥的監管框架和指南已經更加完善和簡化，為其開發和批准提供了明確的途徑。這給醫療保健界注入了信心，並導致生物相似藥的採用增加。隨著生物相似藥市場的擴大，它刺激了蛋白質療法的進一步研究和開發工作。製造商努力開發更先進和差異化的生物相似藥，為市場創造了積極的前景。

人口老化加劇

人口老化的加劇對市場有正面影響。隨著全球人口老化，阿茲海默症、帕金森氏症、黃斑部病變和骨質疏鬆症等與年齡相關的疾病和病症的盛行率更高。正在開發和利用蛋白質療法來解決老齡化人口面臨的這些特定健康挑戰。此外，蛋白質療法為與年齡相關的疾病提供了有針對性的治療選擇，與傳統療法相比，可以提高療效並減少副作用。它們可以針對特定的分子途徑並解決這些疾病的潛在機制，從而改善患者的治療結果和生活品質。此外，老齡化人口不斷成長的產品需求正在推動市場成長。製藥公司和研究機構正在投資開發新型蛋白質療法，以滿足這一人群的特定需求。此外，日益成長的老齡化人口為蛋白質治療創造了更大的市場，促使製造商擴大產品組合併增加產量。這反過來又導致蛋白質療法的更廣泛應用並進一步推動市場成長。

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 數據來源
    • 主要來源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球蛋白質治療市場

  • 市場概況
  • 市場表現
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：依產品

  • 單株抗體 (mAb)
    • 市場趨勢
    • 市場預測
  • 人類胰島素
    • 市場趨勢
    • 市場預測
  • 促紅血球生成素
    • 市場趨勢
    • 市場預測
  • 凝血因子
    • 市場趨勢
    • 市場預測
  • 融合蛋白
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 7 章：市場區隔：依治療領域

  • 代謝紊亂
    • 市場趨勢
    • 市場預測
  • 免疫系統疾病
    • 市場趨勢
    • 市場預測
  • 血液系統疾病
    • 市場趨勢
    • 市場預測
  • 癌症
    • 市場趨勢
    • 市場預測
  • 荷爾蒙失調
    • 市場趨勢
    • 市場預測
  • 遺傳性疾病
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 8 章：市場區隔：按功能

  • 酶活性和調節活性
    • 市場趨勢
    • 市場預測
  • 特別目標活動
    • 市場趨勢
    • 市場預測
  • 疫苗
    • 市場趨勢
    • 市場預測
  • 蛋白質診斷
    • 市場趨勢
    • 市場預測

第 9 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場趨勢
    • 市場細分：按國家/地區
    • 市場預測

第 10 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 13 章：價格分析

第14章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Amgen Inc.
    • Abbott Laboratories
    • Abbvie Inc.
    • Baxter International Inc.
    • Biogen Inc.
    • Csl Behring LLC (CSL Limited)
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG (Roche Holding AG)
    • Johnson & Johnson
    • Merck & Co. Inc.
    • Novo Nordisk A/S (Novo Holdings A/S)
    • Pfizer Inc.
Product Code: SR112024A2431

The global protein therapeutics market size reached US$ 345.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 603.5 Billion by 2032, exhibiting a growth rate (CAGR) of 6.2% during 2024-2032. The increasing prevalence of chronic diseases such as cancer, diabetes, cardiovascular diseases, and autoimmune disorders, the rapid technological advancements in protein engineering, the expanding biopharmaceutical industry, and the widespread product applications in diverse therapeutic areas are some factors propelling the market.

Protein therapeutics is a class of medical treatments utilizing proteins or peptides to prevent, manage, or cure diseases. These therapeutics are designed to target specific molecules or pathways within the body, providing a highly targeted approach to treatment. They offer innovative solutions for a wide range of conditions, including cancer, autoimmune disorders, genetic diseases, and more. They can be derived from natural sources or produced through recombinant DNA technology, allowing for the development of highly specific and potent therapies. These therapeutic proteins can take various forms, including monoclonal antibodies, growth factors, enzymes, and cytokines. They interact with specific receptors or molecules in the body, modulating cellular processes, inhibiting or stimulating immune responses, or directly targeting disease-causing agents. The advantages of protein therapeutics lie in their high specificity, potency, and low toxicity. They often offer improved efficacy and fewer side effects than traditional small-molecule drugs. They have significantly advanced the field of medicine, providing novel treatment options and improving patient outcomes across various diseases.

The global market is majorly driven by the increasing focus on personalized medicine. In line with this, the rising research and development activities and the expanding healthcare infrastructure are significantly contributing to the market. Furthermore, the advancements in manufacturing processes are expected to fuel the market. Apart from this, the breakthroughs in genetic engineering, protein synthesis, and production technologies have enhanced the efficiency and effectiveness of protein therapeutics, positively influencing the market. Moreover, the growing prevalence of chronic diseases such as cancer, diabetes, cardiovascular disorders, and autoimmune diseases is catalyzing the market. Besides, the widespread applications of protein therapeutics in oncology are stimulating the market. Additionally, the rapid innovations in drug delivery systems have improved the delivery of protein therapeutics, enhancing their efficacy and patient compliance. Novel delivery methods such as sustained-release formulations, nanoparticles, and targeted drug delivery systems are driving the market growth by increasing the therapeutic potential of protein drugs.

Protein Therapeutics Market Trends/Drivers:

Growing biopharmaceutical research and development investments

Biopharmaceutical companies and research institutions are increasingly focusing on the development of protein-based drugs due to their high specificity, efficacy, and targetability. The rise in R&D investments in the biopharmaceutical sector is fueling advancements in protein therapeutics. These investments support research activities related to protein engineering, drug discovery, and formulation optimization, leading to the development of novel and improved protein therapeutics. Furthermore, the substantial funds allocated to R&D enable researchers to explore new therapeutic targets, optimize protein structures for enhanced activity, and conduct extensive preclinical and clinical trials. These efforts contribute to the expansion of the market by introducing innovative treatments for various diseases. Moreover, the growing R&D investments facilitate the scaling-up of production processes for protein therapeutics, making them more accessible and cost-effective. This enables increased commercialization and market penetration of protein-based drugs.

Expansion of biosimilars

The expansion of the biosimilars market is significantly contributing to the market. Biosimilars are biologic drugs that are highly similar to approved reference protein therapeutics. As patents for several blockbuster biologics expire, the market for biosimilars is expanding rapidly. The availability of biosimilars provides cost-effective alternatives to expensive protein therapeutics, making them more accessible to patients and healthcare systems. This increased affordability enhances patient access to necessary treatments, driving market growth. Furthermore, the introduction of biosimilars fosters competition in the market. Competition leads to price reductions, encouraging market expansion and creating opportunities for biosimilar manufacturers and reference protein therapeutics companies to innovate and improve their products. Moreover, the regulatory frameworks and guidelines for biosimilars have become more established and streamlined, providing a clear pathway for their development and approval. This has instilled confidence in the healthcare community and resulted in increased biosimilar adoption. As the biosimilars market expands, it stimulates further research and development efforts in protein therapeutics. Manufacturers strive to develop more advanced and differentiated biosimilars, creating a positive outlook for the market.

Rising aging population

The rising aging population is positively influencing the market. As the global population ages, there is a higher prevalence of age-related diseases and conditions such as Alzheimer's disease, Parkinson's disease, macular degeneration, and osteoporosis. Protein therapeutics are being developed and utilized to address these specific health challenges the aging population faces. Furthermore, protein therapeutics offer targeted treatment options for age-related diseases, providing improved efficacy and reduced side effects as compared to traditional therapies. They can target specific molecular pathways and address the underlying mechanisms of these diseases, thereby improving patient outcomes and quality of life. Moreover, the increasing product demand among the aging population is driving market growth. Pharmaceutical companies and research institutions are investing in the development of novel protein therapeutics to meet the specific needs of this demographic. Additionally, the growing aging population creates a larger market for protein therapeutics, prompting manufacturers to expand their product portfolios and increase production. This, in turn, leads to a wider availability of protein therapeutics and further drives market growth.

Protein Therapeutics Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global protein therapeutics market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on product, therapy area, and function.

Breakup by Product:

Monoclonal Antibodies (mAbs)

Human Insulin

Erythropoietin

Clotting Factors

Fusion Protein

Others

Monoclonal Antibodies (mAbs) dominates the market

The report has provided a detailed breakup and analysis of the market based on product. This includes monoclonal antibodies (mAbs), human insulin, erythropoietin, clotting factors, fusion protein, and others. According to the report, monoclonal antibodies (mAbs) represented the largest segment.

Monoclonal antibodies (mAbs) are extensively used to treat cancer, autoimmune disorders, and inflammatory diseases. The increasing prevalence of these conditions, coupled with advancements in antibody engineering and production technologies, drives the demand for mAbs and contributes to the market growth.

On the other hand, human insulin is a vital protein therapeutic for managing diabetes. With the rising incidence of diabetes worldwide, the demand for insulin and insulin analogs is increasing, leading to market growth in this segment. Moreover, erythropoietin (EPO) is another important therapeutic protein stimulating red blood cell production. It is used to treat anemia, particularly in patients with chronic kidney disease and cancer undergoing chemotherapy. The expanding patient pool requiring EPO therapy is driving the growth of this segment.

Besides this, the clotting factors are proteins essential for blood clotting. They are used to manage bleeding disorders such as hemophilia. The growing awareness, diagnosis, and treatment of hemophilia fuel the demand for clotting factors and contribute to the market. In addition, fusion proteins, which combine two or more functional protein domains, have gained significant attention in the development of innovative therapeutics. They offer unique treatment approaches for various diseases, including cancer and autoimmune disorders, thus driving the market in this segment.

Breakup by Therapy Area:

Metabolic Disorders

Immunological Disorders

Hematological Disorders

Cancer

Hormonal Disorders

Genetic Disorders

Others

Metabolic Disorders holds the largest share of the market

A detailed breakup and analysis of the market based on the therapy area have also been provided in the report. This includes metabolic disorders, immunological disorders, hematological disorders, cancer, hormonal disorders, genetic disorders, and others. According to the report, metabolic disorders accounted for the largest market share.

Metabolic disorders encompass conditions such as diabetes, obesity, and hypercholesterolemia. Protein therapeutics, such as insulin for diabetes management, are crucial in treating and controlling these disorders. The rising prevalence of metabolic disorders, coupled with the increasing demand for targeted and effective treatments, is driving the growth of the market in this segment.

On the contrary, immunological disorders, including autoimmune diseases and inflammatory conditions, represent another significant therapy area for protein therapeutics. Monoclonal antibodies and other protein-based drugs modulate the immune system and target specific disease pathways. The growing incidence of immunological disorders and the expanding range of approved protein therapeutics for these conditions are driving the market.

In addition, cancer remains one of the primary drivers of the market. Protein-based therapies, including monoclonal antibodies, antibody-drug conjugates, and immune checkpoint inhibitors, have revolutionized cancer treatment. The increasing incidence of cancer globally, coupled with the development of targeted therapies and immunotherapies, is propelling the growth of the market in oncology.

Breakup by Function:

Enzymatic and Regulatory Activity

Special Targeting Activity

Vaccines

Protein Diagnostics

A detailed breakup and analysis of the market based on the function have also been provided in the report. This includes enzymatic and regulatory activity, special targeting activity, vaccines, and protein diagnostics.

Protein therapeutics with enzymatic and regulatory activity are vital in modulating biological processes and metabolic pathways. These proteins act as enzymes, receptors, or signaling molecules, offering therapeutic benefits in various diseases. The development of novel protein therapeutics with specific enzymatic or regulatory functions drives market growth in this segment.

Furthermore, special targeting activity refers to protein therapeutics targeting certain cells, tissues, or molecular targets. Monoclonal antibodies and antibody-drug conjugates are examples of protein therapeutics with special targeting activity. They can precisely recognize and bind to specific molecules or cells, providing highly targeted therapies. The increasing demand for targeted treatments in conditions such as cancer and autoimmune diseases fuels the growth of protein therapeutics in this segment.

Moreover, vaccines are another significant segment in the market. Protein-based vaccines utilize specific proteins or peptides to stimulate an immune response and confer immunity against infectious diseases. The global focus on vaccination programs, the emergence of new infectious diseases, and the need for improved vaccine technologies drive market growth in this segment.

Besides, protein diagnostics involves using proteins or protein-based assays for diagnostic purposes. These diagnostics can detect specific proteins or biomarkers associated with diseases, aiding in early detection, disease monitoring, and personalized treatment. The growing demand for accurate and reliable diagnostic tools fuels the growth of protein diagnostics and contributes to the overall market.

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance, accounting for the largest protein therapeutics market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.

North America, particularly the United States, holds a significant market share. The region benefits from advanced healthcare infrastructure, a strong presence of biopharmaceutical companies, and robust research and development activities. The presence of key players and extensive investments in protein therapeutics research contribute to market growth in North America. Additionally, the high prevalence of chronic diseases, a large aging population, and favorable reimbursement policies further drive the market in the region.

On the other hand, Asia Pacific is emerging as a rapidly growing market. The region has a large population base, increasing healthcare expenditure, and a rising prevalence of chronic diseases. Countries such as China, Japan, and India are witnessing substantial growth in the biopharmaceutical industry and investing in research and development. Moreover, the increasing awareness of personalized medicine and growing demand for cost-effective treatment options are driving the adoption of protein therapeutics in Asia Pacific.

Competitive Landscape:

Top companies are investing heavily in scientific research to identify new therapeutic targets and develop protein-based drugs with enhanced efficacy and safety profiles. They leverage their protein engineering, molecular biology, and biotechnology expertise to design and optimize therapeutic proteins. Furthermore, these companies establish strategic collaborations with academic institutions, research organizations, and other pharmaceutical companies to access new technologies, expand their pipelines, and accelerate development. Collaborations enable the exchange of knowledge, resources, and expertise, fostering innovation and driving the market. Moreover, successful commercialization strategies play a vital role in driving market growth. These companies employ robust marketing and sales efforts to promote and distribute their products to healthcare providers and patients worldwide. They conduct extensive clinical trials, generate compelling clinical data, and obtain regulatory approvals to ensure market access. Additionally, the top companies continuously invest in manufacturing capabilities and quality control systems to meet the growing demand and ensure a consistent supply of their products. This commitment to manufacturing excellence helps them meet the needs of patients, healthcare providers, and payers, further driving the market growth.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Amgen Inc.

Abbott Laboratories

Abbvie Inc.

Baxter International Inc.

Biogen Inc.

Csl Behring L.L.C. (CSL Limited)

Eli Lilly and Company

F. Hoffmann-La Roche AG (Roche Holding AG)

Johnson & Johnson

Merck & Co. Inc.

Novo Nordisk A/S (Novo Holdings A/S)

Pfizer Inc.

Recent Developments:

In 2020, Amgen Inc. entered into a collaboration with Adaptive Biotechnologies to develop and commercialize fully human-neutralizing antibodies targeting SARS-CoV-2, the virus that causes COVID-19.

In 2021, Abbott Laboratories received FDA clearance for their Tendyne Transcatheter Mitral Valve Replacement (TMVR) system, a minimally invasive therapy for patients with severe mitral regurgitation.

In 2020, AbbVie Inc. acquired Allergan, a pharmaceutical company known for its portfolio of aesthetic and therapeutic products, including Botox.

Key Questions Answered in This Report

  • 1. What was the size of the global protein therapeutics market in 2023?
  • 2. What is the expected growth rate of the global protein therapeutics market during 2024-2032?
  • 3. What has been the impact of COVID-19 on the global protein therapeutics market?
  • 4. What are the key factors driving the global protein therapeutics market?
  • 5. What is the breakup of the global protein therapeutics market based on the product?
  • 6. What is the breakup of the global protein therapeutics market based on the therapy area?
  • 7. What are the key regions in the global protein therapeutics market?
  • 8. Who are the key players/companies in the global protein therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Protein Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Monoclonal Antibodies (mAbs)
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Human Insulin
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Erythropoietin
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Clotting Factors
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Fusion Protein
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Therapy Area

  • 7.1 Metabolic Disorders
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Immunological Disorders
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Hematological Disorders
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Cancer
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Hormonal Disorders
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Genetic Disorders
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Others
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast

8 Market Breakup by Function

  • 8.1 Enzymatic and Regulatory Activity
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Special Targeting Activity
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Vaccines
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Protein Diagnostics
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Amgen Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Abbott Laboratories
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Abbvie Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Baxter International Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Biogen Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Csl Behring L.L.C. (CSL Limited)
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7 Eli Lilly and Company
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 F. Hoffmann-La Roche AG (Roche Holding AG)
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 SWOT Analysis
    • 14.3.9 Johnson & Johnson
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Merck & Co. Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Novo Nordisk A/S (Novo Holdings A/S)
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Pfizer Inc.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Protein Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Protein Therapeutics Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Protein Therapeutics Market: Breakup by Product (in %), 2023
  • Figure 4: Global: Protein Therapeutics Market: Breakup by Therapy Area (in %), 2023
  • Figure 5: Global: Protein Therapeutics Market: Breakup by Function (in %), 2023
  • Figure 6: Global: Protein Therapeutics Market: Breakup by Region (in %), 2023
  • Figure 7: Global: Protein Therapeutics Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 8: Global: Protein Therapeutics (Monoclonal Antibodies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Protein Therapeutics (Monoclonal Antibodies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Protein Therapeutics (Human Insulin) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Protein Therapeutics (Human Insulin) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Protein Therapeutics (Erythropoietin) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Protein Therapeutics (Erythropoietin) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Protein Therapeutics (Clotting Factors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Protein Therapeutics (Clotting Factors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Protein Therapeutics (Fusion Protein) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Protein Therapeutics (Fusion Protein) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Protein Therapeutics (Other Products) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Protein Therapeutics (Other Products) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Protein Therapeutics (Metabolic Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Protein Therapeutics (Metabolic Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Protein Therapeutics (Immunological Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Protein Therapeutics (Immunological Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Protein Therapeutics (Hematological Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Protein Therapeutics (Hematological Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Protein Therapeutics (Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Protein Therapeutics (Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Protein Therapeutics (Hormonal Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Protein Therapeutics (Hormonal Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Protein Therapeutics (Genetic Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Protein Therapeutics (Genetic Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Global: Protein Therapeutics (Other Therapy Areas) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Global: Protein Therapeutics (Other Therapy Areas) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Global: Protein Therapeutics (Enzymatic and Regulatory Activity) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Global: Protein Therapeutics (Enzymatic and Regulatory Activity) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Global: Protein Therapeutics (Special Targeting Activity) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Global: Protein Therapeutics (Special Targeting Activity) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Global: Protein Therapeutics (Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Global: Protein Therapeutics (Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Global: Protein Therapeutics (Protein Diagnostics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Global: Protein Therapeutics (Protein Diagnostics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: North America: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: North America: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: United States: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: United States: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Canada: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Canada: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Asia Pacific: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Asia Pacific: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: China: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: China: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Japan: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Japan: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: India: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: India: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: South Korea: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: South Korea: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Australia: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Australia: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Indonesia: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Indonesia: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Others: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Others: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Europe: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Europe: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Germany: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Germany: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: France: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: France: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: United Kingdom: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: United Kingdom: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Italy: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Italy: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Spain: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Spain: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Russia: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Russia: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Others: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Others: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 80: Latin America: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 81: Latin America: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 82: Brazil: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 83: Brazil: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 84: Mexico: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 85: Mexico: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 86: Others: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 87: Others: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 88: Middle East and Africa: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 89: Middle East and Africa: Protein Therapeutics Market: Breakup by Country (in %), 2023
  • Figure 90: Middle East and Africa: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 91: Global: Protein Therapeutics Industry: SWOT Analysis
  • Figure 92: Global: Protein Therapeutics Industry: Value Chain Analysis
  • Figure 93: Global: Protein Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Protein Therapeutics Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Protein Therapeutics Market Forecast: Breakup by Product (in Million US$), 2024-2032
  • Table 3: Global: Protein Therapeutics Market Forecast: Breakup by Therapy Area (in Million US$), 2024-2032
  • Table 4: Global: Protein Therapeutics Market Forecast: Breakup by Function (in Million US$), 2024-2032
  • Table 5: Global: Protein Therapeutics Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Protein Therapeutics Market Structure
  • Table 7: Global: Protein Therapeutics Market: Key Players